NIH Reporter #5I01RX003415-07

Clinical Trial Research Services for Romosozumab in Spinal Cord Injury Patients

This opportunity from the JAMES J PETERS VA MEDICAL CENTER seeks research services for a clinical trial evaluating romosozumab in patients with chronic spinal cord injury. - Government Buyer: - JAMES J PETERS VA MEDICAL CENTER (Veterans Affairs, Bronx, NY) - OEMs and Vendors: - Romosozumab is the primary pharmaceutical product; no specific OEMs or vendors are named, but Amgen is the known manufacturer of romosozumab - Products/Services Requested: - Romosozumab (medication for clinical trial) - Clinical trial research services, including: - Study design - Patient recruitment - Biomarker analysis - Outcome measurement - Unique/Notable Requirements: - Expertise in bone mineral density assessment - Experience with chronic spinal cord injury populations - Ability to conduct clinical research involving pharmaceuticals - The project aims to improve standard care for spinal cord injury patients by evaluating the effectiveness of romosozumab on bone health.

Description

This is a clinical trial for testing romosozumab to improve bone density in individuals with chronic spinal cord injury. The project is funded by the Veterans Affairs and is scheduled for 2026-2027. The project involves multiple specific aims related to bone mineral density and biomarkers, with potential to change standard care practices.

View original listing